3 Results for "

PACMA31

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "PACMA31" in MCE Product Catalog:

6
6 Cited Publications
Cat. No.: HY-100433
CAS No.: 1401089-31-3
Purity:  99.32%
Target:  

PDI

Research Areas:  

Cancer

PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-100433R
CAS No.: 1401089-31-3
Target:  

PDI Reference Standards

Research Areas:  

Cancer

PACMA 31 (Standard) is the analytical standard of PACMA 31 (HY-100433). This product is intended for research and analytical applications. PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-183406
CAS No.: 102616-62-6
Research Areas:  

Neurological Disease Cancer

AS15 is a PDIA1 inhibitor with an IC50 value of 300 nM. AS15 interacts with the active-site cysteine of PDIA1, and this process is independent of the substrate-binding domain of PDIA1. AS15 acts as a synergistic cell growth inhibitor with buthionine sulfoximine (BSO) (HY-106376), a glutathione synthesis inhibitor. AS15 can be used in the research of glioblastoma .
loading...
    loading...